The Brown University Psychopharmacology Update最新文献

筛选
英文 中文
Your Medication Information 您的用药信息
The Brown University Psychopharmacology Update Pub Date : 2025-01-29 DOI: 10.1002/pu.31283
{"title":"Your Medication Information","authors":"","doi":"10.1002/pu.31283","DOIUrl":"https://doi.org/10.1002/pu.31283","url":null,"abstract":"<p>Duloxetine (generic) — Cymbalta (brand)</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 3","pages":"9-10"},"PeriodicalIF":0.0,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143120841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Meta-analysis finds viloxazine effective for youths with ADHD 元分析发现维洛沙嗪对患有多动症的青少年有效
The Brown University Psychopharmacology Update Pub Date : 2025-01-29 DOI: 10.1002/pu.31281
{"title":"Meta-analysis finds viloxazine effective for youths with ADHD","authors":"","doi":"10.1002/pu.31281","DOIUrl":"https://doi.org/10.1002/pu.31281","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 3","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143120843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study finds zuranolone impairs simulated driving performance
The Brown University Psychopharmacology Update Pub Date : 2025-01-29 DOI: 10.1002/pu.31280
{"title":"Study finds zuranolone impairs simulated driving performance","authors":"","doi":"10.1002/pu.31280","DOIUrl":"https://doi.org/10.1002/pu.31280","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 3","pages":"6-8"},"PeriodicalIF":0.0,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143120449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug-associated neuroleptic malignant syndrome
The Brown University Psychopharmacology Update Pub Date : 2025-01-29 DOI: 10.1002/pu.31275
Y. W. Francis Lam Pharm.D., FCCP
{"title":"Drug-associated neuroleptic malignant syndrome","authors":"Y. W. Francis Lam Pharm.D., FCCP","doi":"10.1002/pu.31275","DOIUrl":"https://doi.org/10.1002/pu.31275","url":null,"abstract":"<p>Neuroleptic malignant syndrome (NMS) is an uncommon but serious and potentially fatal adverse drug effect caused by dopamine receptor blockade. The syndrome is most closely associated with use of typical, and less frequently atypical, antipsychotics, with an incidence rate of up to 1.4% in patients being treated with these drugs. However, other drugs acting as D2 receptor antagonists, such as antihistamines and antiemetics, can also cause the syndrome. Antidepressants, carbamazepine, and lithium (Konstantakopoulos et al., 2009; Patil et al., 2016) have sometimes been implicated as possible exacerbating factors.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 3","pages":"2"},"PeriodicalIF":0.0,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143120848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment discontinuation less likely with methadone than buprenorphine/naloxone
The Brown University Psychopharmacology Update Pub Date : 2024-12-24 DOI: 10.1002/pu.31267
{"title":"Treatment discontinuation less likely with methadone than buprenorphine/naloxone","authors":"","doi":"10.1002/pu.31267","DOIUrl":"https://doi.org/10.1002/pu.31267","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 2","pages":"7"},"PeriodicalIF":0.0,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143110248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Elinzanetant effective for menopausal vasomotor symptoms
The Brown University Psychopharmacology Update Pub Date : 2024-12-24 DOI: 10.1002/pu.31265
{"title":"Elinzanetant effective for menopausal vasomotor symptoms","authors":"","doi":"10.1002/pu.31265","DOIUrl":"https://doi.org/10.1002/pu.31265","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 2","pages":"6-7"},"PeriodicalIF":0.0,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143118881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quetiapine co-administration with fluvoxamine and duloxetine 喹硫平与氟伏沙明和度洛西汀联合用药
The Brown University Psychopharmacology Update Pub Date : 2024-12-24 DOI: 10.1002/pu.31262
Y. W. Francis Lam Pharm.D., FCCP
{"title":"Quetiapine co-administration with fluvoxamine and duloxetine","authors":"Y. W. Francis Lam Pharm.D., FCCP","doi":"10.1002/pu.31262","DOIUrl":"https://doi.org/10.1002/pu.31262","url":null,"abstract":"<p>Atypical antipsychotics are frequently used in conjunction with selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine/serotonin reuptake inhibitors (SNRIs), but data on potential pharmacokinetic interactions between specific combinations are limited.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 2","pages":"2"},"PeriodicalIF":0.0,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143118784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
LAI antipsychotics show effective results in comparative analysis
The Brown University Psychopharmacology Update Pub Date : 2024-12-24 DOI: 10.1002/pu.31263
{"title":"LAI antipsychotics show effective results in comparative analysis","authors":"","doi":"10.1002/pu.31263","DOIUrl":"https://doi.org/10.1002/pu.31263","url":null,"abstract":"<p>Long-acting injectable (LAI) formulations of paliperidone and aripiprazole were among the most effective antipsychotics for limiting patient relapse in a comparative effectiveness study using health care register data for patients with schizophrenia. The 3-month formulation of LAI paliperidone was associated with the lowest risk of the adverse outcomes.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 2","pages":"3-4"},"PeriodicalIF":0.0,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143118791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Weight-loss drugs appear beneficial for patients with substance use disorders 减肥药物似乎对药物使用障碍患者有益
The Brown University Psychopharmacology Update Pub Date : 2024-12-24 DOI: 10.1002/pu.31260
{"title":"Weight-loss drugs appear beneficial for patients with substance use disorders","authors":"","doi":"10.1002/pu.31260","DOIUrl":"https://doi.org/10.1002/pu.31260","url":null,"abstract":"<p>Drugs in medication classes commonly used to treat type 2 diabetes and obesity appear to improve substance use outcomes in patients with opioid use disorder (OUD) and alcohol use disorder (AUD), a retrospective cohort study has found. Patients receiving these medications experienced significantly lower rates of opioid overdose and alcohol intoxication. Study results were published online Oct. 16, 2024, in <i>Addiction</i>.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 2","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143118793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Review: Haloperidol, fluphenazine, clozapine show poor results on cognition
The Brown University Psychopharmacology Update Pub Date : 2024-12-24 DOI: 10.1002/pu.31261
{"title":"Review: Haloperidol, fluphenazine, clozapine show poor results on cognition","authors":"","doi":"10.1002/pu.31261","DOIUrl":"https://doi.org/10.1002/pu.31261","url":null,"abstract":"<p>A systematic review and network meta-analysis encompassing 68 randomized trials has concluded that the antipsychotics haloperidol, fluphenazine, and clozapine ranked lowest on measures of cognition in patients with schizophrenia and related disorders. There were few clear differences overall among the antipsychotics studied, the investigators reported. Results were published online Oct. 16, 2024, in <i>JAMA Psychiatry</i>.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 2","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143118794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信